PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Two climbers, an American and a Swiss, die from exhaustion in first fatalities on Everest this year

Show Me

Over 15,000 Gas Stations Out of Fuel Nationwide

Show Me

Rep. Liz Cheney Leaves Door Open for 2024 Presidential Run, Won’t Leave GOP

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 13, 2021 | Video: 48 Minutes 33 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 13, 2021 | Video: 48 Minutes 37 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 13, 2021 | Video: 48 Minutes 59 Seconds

Show Me

BREAKING: Maricopa County Elections Officials DELETED ENTIRE DATABASE from Voting Machines – Including “All Election Information” from Main Database

Show Me

‘American Idol’ finalist Caleb Kennedy out after KKK-themed video surfaces

Show Me

Over A Year Into The Pandemic, Politicians Are Still Getting Caught Ignoring Their Own COVID Restrictions

Show Me

Former Ellen producer SLAMS DeGeneres for ‘duping fans into believing she’s a nice person’

Show Me

Facebook board upholds Trump suspension

Show Me

Newsmax Apologizes for False Claims of Vote-Rigging by a Dominion Employee

Show Me

Robert Downey Junior Discusses The Movie Tropic Thunder | Video: 10 Minutes 54 Seconds

Show Me

Medical Racism: The New Apartheid | Video: 3 Minutes 38 Seconds

Show Me

Biden Admin To Resume Construction On Border Wall Amid Crisis

Show Me

San Diego Sector Border Patrol has apprehended dozens of sex offenders so far in fiscal year 2021

Show Me

Santa Clara U. President Resigns After Inappropriate Behavior, Officials Say

Show Me

Children could soon get a COVID vaccine after Maryland kids pave way in trial

Show Me

Cryptocurrency market tanks after Tesla suspends bitcoin transactions

Show Me

Arizona Adopts Election Reform Bill That Stops Some Voters from Automatically Receiving Absentee Ballots

Show Me

Schools ditch student mask requirements in growing numbers

Show Me

MSNBC’s Melber: Cheney Ouster All to Appease the ‘Deceitful Vanity’ of ‘One Blogger in Florida’

Show Me

124 Retired Generals Warn of Marxist Threat

Show Me

Detroit on use of Zuckerberg’s CTCL election funding: ‘We have created a new normal’

Show Me

Dominion Worker Drops Newsmax From Lawsuit After Network Apologizes for Allegations

Show Me

Man convicted of consensual gay sex in the ’90s doesn’t have to register as sex offender: judge

Show Me

The real steal is coming

Show Me

New survey of US Jews reveals worries, strengths, divisions

Show Me

Don Lemon Begs Mother to Follow Science and … Take Off Her Mask

Show Me

Schumer: ‘The big lie is spreading like a cancer’ among GOP

Show Me

May 12, 2021 | Nightly News Rebroadcast | Video: 50 Minutes 40 Seconds

Show Me

To Many Americans It Seems Official: With Biden In Office The Same Old Warmongers Are Back In Power | The Middle East Continues To Fall Apart Without Trump Peace Policies

Show Me

Who is Miles Taylor, author of the ‘Anonymous’ NYT op-ed on Trump?

Show Me

‘Rationals’ vs. ‘radicals’: Anti-Trump Republicans threaten third party

Show Me

UN Warns of ‘Full Scale War’ Between Israel, Palestinians After Residential Building Collapses

Show Me

Oops! | “Seychelles brings back curbs despite vaccination success”

Show Me

EXC: Fauci-Funded Researchers Headlined Wuhan Lab ‘Gain Of Function’ Conference.

Show Me

US Protests Over Israeli-Palestinian Conflict Ignite In Major Cities

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 12, 2021 | Video: 47 Minutes 46 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 12, 2021 | Video: 47 Minutes 48 Seconds

Show Me